Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single Arm, Multi-center, Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-pulmonary Vein Sources of Atrial Fibrillation and Guide Ablation Therapy.

NCT05883631 is registered in ClinicalTrials.gov with Cortex as lead sponsor.

NCT NCT05883631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05883631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single Arm, Multi-center, Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-pulmonary Vein Sources of Atrial Fibrillation and Guide Ablation Therapy.
Lead sponsor
Cortex
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 23, 2023
Completion date
January 31, 2026
Enrollment
400 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

arrhythmia, arrhythmias, cardiac, atrial arrhythmia, atrial fibrillation, atrial fibrillation paroxysmal, atrial fibrillation, paroxysmal or persistent, atrial fibrillation, persistent, atrial flutter, atrial tachycardia